Comparison of Two sTRAtegies For the Non-Invasive Diagnosis of advanCed Liver Fibrosis in NAFLD

Inclusion Criteria: 1. Presence of NAFLD as defined by : * The presence of liver steatosis as assessed by ultrasonography (bright liver) or magnetic resonance imaging/spectroscopy (fat fraction \>5.6%) or Controlled Attenuation Parameter (≥248 dB/m) * The absence of steatosis-inducing drugs (systemic corticosteroids, methotrexate, amiodarone, tamoxifen) * The absence of excessive alcohol consumption (\<210 g/week in men or \<140 g/week in women) * The absence of other causes of chronic liver disease (chronic viral hepatitis B or C, hemochromatosis, auto-immune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease alpha-1-antitrypsin deficiency). 2. Age ≥18 years and ≤80 years 3. Affiliated person or beneficiary of a social security regime 4. Written informed consent of the patient who agree to comply with the study protocol. Exclusion Criteria: 1. Decompensated cirrhosis (ascites, variceal bleeding, hepatic encephalopathy, liver failure, hepato-renal syndrome) 2. Hepatocellular carcinoma 3. Inability to safely undergo liver biopsy 4. Participation in other intervention study with drug protocol treatment in progress at the time of inclusion or within one month prior to inclusion in the study. 5. Pregnant, breastfeeding or parturient woman 6. Person restricted by judicial or administrative decision 7. Person under psychiatric care under restraint 8. Person subject to a legal protection measure 9. Person unable to express consent